id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2021-D-1140-0002,FDA,FDA-2021-D-1140,Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations; Draft Guidance for Sponsor-Investigators; Availability,Other,Guidance,2021-12-08T05:00:00Z,2021,12,2021-12-08T05:00:00Z,2022-02-08T04:59:59Z,2024-11-07T00:35:20Z,,1,0,0900006484eafc3e
FDA-2021-D-1140-0001,FDA,FDA-2021-D-1140,Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations; Draft Guidance for Sponsor-Investigators; Availability,Notice,Notice of Availability,2021-12-08T05:00:00Z,2021,12,2021-12-08T05:00:00Z,,2021-12-08T14:19:49Z,2021-26453,0,0,0900006484eaeede